Antagonists of the P2Y₁₂ ADP receptor, in addition to aspirin, are the mainstay of treatment of non-ST elevation acute coronary syndromes (NSTE-ACS).  Although Clopidogrel (Plavix^®) has been widely used for years, newer agents have come into use, including Ticagrelor (Brilinta^®) and Prasugrel (Effient^®).  You have probably seen Cardiology recommending Prasugrel + Aspirin along with their coronary stent at Olive View.  The following article from the TRITON study demonstrates the efficacy of Prasugrel.

What about Ticagrelor? You may have seen this as well after ACS or a coronary stent, especially at UCLA.  The additional further reading article is the landmark study for demonstrating its benefits.

The 2014 American Heart Association – American College of Cardiology guidelines currently recommend either Clopidogrel, Prasugrel, or Ticagrelor for patients receiving PCI.